Patients with multiple myeloma (MM) had significantly increased rates of complete response (CR) and progression-free survival (PFS)—including superior PFS across poor prognosis subgroups—when postautologous stem cell transplantation (ASCT) consolidation therapy utilized bortezomib-thalidomide-dexamethasone compared with thalidomide-dexamethasone, investigators reported during the 53rd American Society of Hematology Annual Meeting and Exposition.
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.